MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2024 International Congress

September 27-October 1, 2024. Philadelphia, PA.

View by Title View Categories
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial

    W. Singer, S. Zanigni, L. Kjærsgaard, J. Wiedemann, P. Kallunki, K. Kompus, M. Jørgensen, M. Flensburg, A. Bidani, JL. Molinuevo, A. Takeda, B. Grønning, J. Luthman (Rochester, USA)

  • Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial

    D. Lynch, A. Duquette, M. França Jr, S. Perlman, A. Durr, E. Bertini, A. Darling, K. Mathews, L. Schöls, A. Fournier, M. Delatycki, S. Subramony, R. Roxburgh, O. Zhang, C. Rummey, A. Salvucci, B. Yao, J. Cherry, L. Golden, T. Zesiewicz (Philadelphia, USA)

  • Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

    H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (New York, USA)

  • Safety and Tolerability of Ecopipam in Tourette Syndrome (TS) with Psychiatric Comorbidities.

    D. Gilbert, S. Atkinson, G. Karkanias, R. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

  • Safety and tolerability of opicapone in Parkinson’s Disease: from early-stage (EPSILON study) to late-stage (BIPARK studies)

    G. Cordeiro, I. Peixoto, H. Gama, L. Magalhães, J. Moreira, J-F. Rocha, J. Holenz (Trofa, Portugal)

  • Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

    A. Berrio, L. Chrones, V. Abler, R. Hauser (San Diego, USA)

  • Safety of staged bilateral MR-guided focused ultrasound thalamotomy for essential tremor

    M. Kaplitt, H. Sarva, V. Krishna, HM. Eisenberg, WJ. Elias, P. Ghanouni, GH. Baltuch, A. Rezai, C. Halpern, B. Dalm, P. Fishman, V. Buch, S. Moosa, AM. Murray (New York, USA)

  • SAGE-324/BIIB124, an investigational GABAA receptor PAM, for treatment of essential tremor

    P. Lewitt, H. Jinnah, R. Pahwa, A. Ellenbogen, R. Kumar, TM. Lieu, B. Hersh, R. Chuang, C. Vaudreuil, Z. Berger, D. Arkilo, SH. Kuo (Bloomfield, USA)

  • Salford’s Community Based Movement Disorder Service: Providing integrated care for people in their own homes.

    T. Jones, C. Miller, C. Lim (Salford, United Kingdom)

  • Salivary and Plasma Heme Oxygenase-1 Concentration as a New Potential Biomarker in Parkinson Disease

    R. Yadav (Kathmandu, Nepal)

  • « Previous Page
  • 1
  • …
  • 143
  • 144
  • 145
  • 146
  • 147
  • …
  • 181
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley